Myocardial effects of VDR activators in renal failure - Wikidata - wikimedia - TriplyDB

Myocardial effects of VDR activators in renal failure

Myocardial effects of VDR activators in renal failure

http://www.wikidata.org/entity/Q34005358

about

A Genetic Biomarker of Oxidative Stress, the Paraoxonase-1 Q192R Gene Variant, Associates with Cardiomyopathy in CKD: A Longitudinal Study Speckle tracking echocardiography detects uremic cardiomyopathy early and predicts cardiovascular mortality in ESRD.Cardiac and renal effects of atrasentan in combination with enalapril and paricalcitol in uremic rats.Vitamin D receptor agonist doxercalciferol modulates dietary fat-induced renal disease and renal lipid metabolism VS-105: a novel vitamin D receptor modulator with cardiovascular protective effects.Differential expression and regulation of Klotho by paricalcitol in the kidney, parathyroid, and aorta of uremic rats.Cardiorenal syndrome and vitamin D receptor activation in chronic kidney disease The influence of selective vitamin D receptor activator paricalcitol on cardiovascular system and cardiorenal protection.Arrhythmia and Sudden Death in Hemodialysis Patients: Protocol and Baseline Characteristics of the Monitoring in Dialysis Study Protective cardiovascular and renal actions of vitamin D and estrogen Vitamin D and the heart.Pediatric cardiomyopathies: causes, epidemiology, clinical course, preventive strategies and therapies.Paricalcitol downregulates myocardial renin-angiotensin and fibroblast growth factor expression and attenuates cardiac hypertrophy in uremic rats.Diabetic microvascular complications: possible targets for improved macrovascular outcomes Vitamin D receptor activation and cardiovascular disease.Vitamin D and the cardiovascular system: an overview of the recent literature.Is left ventricular hypertrophy a modifiable risk factor in end-stage renal disease.Randomized controlled trial of cholecalciferol supplementation in chronic kidney disease patients with hypovitaminosis D.Vitamin D receptor activation, left ventricular hypertrophy and myocardial fibrosis.Paricalcitol modulates ACE2 shedding and renal ADAM17 in NOD mice beyond proteinuria.Regulation of miR-29b and miR-30c by vitamin D receptor activators contributes to attenuate uraemia-induced cardiac fibrosis.

P2860

Q30381312-75EA1ABB-A860-41E5-B6E7-B065323E537B Q30401905-0EE04833-B990-488A-B53C-A3D636FDFDE5 Q34475608-EDEAA070-8839-493A-BFDF-36B98F58EA15 Q34719267-16F29BEE-7B7A-4DED-BFF0-A4A8812C4DC7 Q35287391-E98FD08F-C5DA-4AB6-9394-DFDBD9E6D644 Q35667633-3E906261-665D-441F-9601-1B7BA3D528D6 Q36468531-102D4B32-9A58-4160-A411-73C951882699 Q36613869-861503FD-EDDD-4993-9E26-E035F5F79196 Q36770929-07208896-DEF4-4150-9E98-F003D43E4018 Q36905627-7DE7D190-21D8-4807-8721-EF8740817465 Q37342339-426D83D5-F4F2-49F2-A6A0-7B98056C405E Q37520430-7C6C0411-A599-460B-B5EE-5BC5576CBA20 Q37690771-EC402A50-871A-4C7C-881B-3973462FC03B Q37892915-1CCDDE07-8953-4DC5-A004-199A9F3859D5 Q38069143-F35CC2C5-6E2E-47B6-B80A-408D955C42AF Q38152318-AC6520E6-CD2A-4322-92D5-D869F6444B13 Q38258133-2E4E37C3-1BF8-47B6-9C3D-357156A96C85 Q46290245-A3CB3C84-5D54-4ED5-B783-857A1814516D Q49061065-F874848D-82B6-47CD-9AFC-E60B16B5C599 Q50433834-308B8058-4B09-4D06-B76F-595DA74BBA89 Q51025922-C9E9F015-DDD8-4316-91BA-1B31F75402C0

P2860

Myocardial effects of VDR activators in renal failure

http://www.wikidata.org/entity/Q34005358

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Myocardial effects of VDR activators in renal failure

@ast

Myocardial effects of VDR activators in renal failure

@en

Myocardial effects of VDR activators in renal failure

@nl

type

label

Myocardial effects of VDR activators in renal failure

@ast

Myocardial effects of VDR activators in renal failure

@en

Myocardial effects of VDR activators in renal failure

@nl

prefLabel

Myocardial effects of VDR activators in renal failure

@ast

Myocardial effects of VDR activators in renal failure

@en

Myocardial effects of VDR activators in renal failure

@nl

P1433

Q34005358-DEBAEB9E-32E1-4DB1-A5A7-464980D8A509

P1476

Q34005358-F7AA426D-D049-42FF-8EEE-AB91F2DF80A6

P2093

Q34005358-32384ED9-D381-4965-BD42-D8C38A76FD80

Q34005358-5044F355-3E26-40FB-848B-3F3B12C96B50

Q34005358-50772298-3E54-4D73-9B1A-E1B72A1D7B6D

Q34005358-77C26E27-F458-430C-A340-6AB0121FEDD5

Q34005358-80E4F648-19F6-4AE9-9C16-ADF8A2781779

Q34005358-85830DAB-C6AD-4DE2-A39C-6C6EF648EC24

Q34005358-C55D7A6C-75B3-4F40-8100-5CCF252792E6

P2860

Q34005358-070D59B3-1F97-4989-8D2C-FDC53AFD9903

Q34005358-08203C3A-508D-4A82-9A1A-4EA3AEA93C2F

Q34005358-47D4303D-F07E-4B99-B263-574FC882FE93

Q34005358-4C43CEE9-968D-4414-BC80-D3373D9ED332

Q34005358-4E354F7E-5934-494D-AD3A-51E8066370D4

Q34005358-9DCD24ED-7CA8-4790-A275-DBF9572C7484

Q34005358-A8C1A21A-7BAE-4114-BAB6-6C46DBE4A77C

Q34005358-B4156400-D987-498F-85D8-2202A1B0C28F

Q34005358-C57C0A5E-6BE4-4151-B028-B22F0C37AC7A

Q34005358-EC4556B1-4182-43E7-B0E3-C244E58AACB5

P304

Q34005358-14BE4A9D-A9FA-47DB-B1CB-6FDBDDD5E3C9

P31

Q34005358-7947D2B9-2D65-420A-93F8-D721A68AC19C

P356

Q34005358-090D96E0-6E81-442C-A0B3-CF6E5B8CDF3D

P433

Q34005358-EE6DD512-5C01-48B9-AAB2-0A6660E647F0

P478

Q34005358-B2EF0434-6893-4214-BB87-97C740AEC525

P577

Q34005358-84330573-843B-40F5-A021-BF69E5C0C90D

P5875

Q34005358-AE4225A6-6762-431F-85BE-5FAAD5666E13

P698

Q34005358-A74CB0F5-3CDE-4C4A-9A59-03DCE32DED0B

P932

Q34005358-B5C52A6C-88C6-4108-836F-47843CAC3DBF

P356

J.JSBMB.2010.03.026

P1433

The Journal of Steroid Biochemistry and Molecular Biology

P1476

Myocardial effects of VDR activators in renal failure

@en

P2093

Eduardo Slatopolsky

http://www.w3.org/2001/XMLSchema#string

Helen Liapis

http://www.w3.org/2001/XMLSchema#string

Hironori Nakamura

http://www.w3.org/2001/XMLSchema#string

Jane Finch

http://www.w3.org/2001/XMLSchema#string

Jeremiah Morrissey

http://www.w3.org/2001/XMLSchema#string

Masahide Mizobuchi

http://www.w3.org/2001/XMLSchema#string

Masanori Tokumoto

http://www.w3.org/2001/XMLSchema#string

P2860

Ontogenesis of the vitamin D receptor in rat heart

Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy.

1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system.

Effect of ANG II type I receptor antagonist and ACE inhibitor on vitamin D receptor-null mice.

Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems.

Activated injectable vitamin D and hemodialysis survival: a historical cohort study.

Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients.

Combination therapy with paricalcitol and enalapril ameliorates cardiac oxidative injury in uremic rats.

1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter.

Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats.

P304

188-192

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JSBMB.2010.03.026

http://www.w3.org/2001/XMLSchema#string

P433

1-2

http://www.w3.org/2001/XMLSchema#string

P478

121

http://www.w3.org/2001/XMLSchema#string

P577

2010-03-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

42254676

http://www.w3.org/2001/XMLSchema#string

P698

20236614

http://www.w3.org/2001/XMLSchema#string

P932

2906634

http://www.w3.org/2001/XMLSchema#string